Study guide
11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation
Key Takeaways Explain This Topic AI
Neutropenic Fever is defined as a single oral temperature ≥38.3°C (101.0°F) or ≥38.0°C (100.4°F) sustained over 1 hour, with an ANC <500/mcL (or <1000/mcL with predicted decline below 500/mcL).
Empiric IV anti-pseudomonal beta-lactam monotherapy (Cefepime, Piperacillin-tazobactam, or Meropenem) must be initiated within 60 minutes of presentation after obtaining two sets of blood cultures.
MASCC Risk Index Score ≥21 (out of a maximum attainable score of 26) identifies low-risk candidates for outpatient oral empiric antibiotics (ciprofloxacin plus amoxicillin-clavulanate), whereas a score <21 requires inpatient IV therapy.
Chemotherapy extravasation protocols require immediate infusion cessation, aspiration of residual drug, line removal, elevation, and specific thermal application.
Thermal and antidote management differs strictly by drug class: Anthracyclines require cold compresses and IV Dexrazoxane (Totect) within 6 hours, whereas Vinca Alkaloids require warm compresses and subcutaneous Hyaluronidase injection.
Last updated: August 2026
Hematologic & Cardiovascular Emergencies
Hematologic and cardiovascular emergencies in oncology present acute threats to survival, driven by treatment-induced bone marrow suppression, fulminant systemic infection, or destructive vascular drug extravasation. Neutropenic Fever (NF) , Oncologic Sepsis , and Chemotherapy Vesicant Extravasation represent high-stakes clinical scenarios requiring standardized, evidence-based Advanced Practice Registered Nurse (APRN) emergency management.
1. Neutropenic Fever: Diagnostic Criteria & ANC Calculation
Neutropenic fever is a medical emergency. Due to profound neutropenia, the normal inflammatory response is severely blunted; fever is frequently the only early manifestation of overwhelming bacterial infection.
IDSA / ASCO Diagnostic Criteria
Fever Criteria : A single oral temperature ≥ 38.3 ∘ C \ge 38.3^\circ\text{C} ≥ 38. 3 ∘ C ( 101.0 ∘ F 101.0^\circ\text{F} 101. 0 ∘ F ) OR a sustained temperature ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C ( 100.4 ∘ F 100.4^\circ\text{F} 100. 4 ∘ F ) over a 1-hour period.
Neutropenia Criteria : An Absolute Neutrophil Count (ANC) < 500 / μ L < 500/\mu\text{L} < 500/ μ L , or an ANC < 1000 / μ L < 1000/\mu\text{L} < 1000/ μ L with a predicted decline to < 500 / μ L < 500/\mu\text{L} < 500/ μ L over the subsequent 48 hours.
ANC Calculation Formula ANC (/ μ L) = WBC (/ μ L) × ( % Segmented Neutrophils + % Bands 100 ) \text{ANC (/}\mu\text{L)} = \text{WBC (/}\mu\text{L)} \times \left( \frac{\%\text{Segmented Neutrophils} + \%\text{Bands}}{100} \right) ANC (/ μ L) = WBC (/ μ L) × ( 100 % Segmented Neutrophils + % Bands )
2. Risk Stratification: MASCC Risk Index Score
The Multinational Association for Supportive Care in Cancer (MASCC) Risk Index stratifies patients with neutropenic fever into low-risk and high-risk categories to determine treatment setting.
MASCC Scoring Criteria
- Clinical Characteristic Score Points
- Burden of Illness : Mild or no symptoms 5
- Burden of Illness : Moderate symptoms 3
- No Hypotension (Systolic BP > 90 mmHg > 90\text{ mmHg} > 90 mmHg ) 5
- No Chronic Obstructive Pulmonary Disease (COPD) 4
- Solid Tumor OR Hematologic Malignancy with NO prior fungal infection 4
- No Dehydration requiring IV fluids 3
- Outpatient Status at fever onset 3
- Age < 60 < 60 < 60 years 2
- Maximum Possible Score 26
- Risk Classification & Clinical Triage
MASCC Score ≥ 21 \ge 21 ≥ 21 (Low Risk) : Low risk of severe septic complications ( < 5 % <5\% < 5% mortality). Note that 26 is the maximum attainable score, not the cut point — a frequent exam trap. Eligible for outpatient oral empiric antibiotic therapy (e.g., Ciprofloxacin 500 mg PO Q12H + Amoxicillin-Clavulanate 875 mg PO Q12H) provided close 24-hour telephone follow-up is ensured.
MASCC Score < 21 < 21 < 21 (High Risk) : High risk of severe complications and mortality. Mandates inpatient hospital admission for intravenous broad-spectrum anti-pseudomonal monotherapy.
3. Empiric Antimicrobial Protocol for Neutropenic Fever Neutropenic Fever Identified (Temp >= 38.3°C + ANC < 500)
- │
- ├─► Emergency Diagnostic Workup (< 15 mins): 2 Sets Blood Cultures (1 Peripheral + 1 Central Line Lumen)
- │
- ├─► DOOR-TO-ANTIBIOTIC TIME < 60 MINUTES
- │
├─► First-Line Empiric IV Monotherapy (Anti-pseudomonal Beta-lactam):
- │ ├─► Cefepime 2 g IV Q8H OR Piperacillin-Tazobactam 4.5 g IV Q6H OR Meropenem 1 g IV Q8H
- │
└─► Assess Specific Indications for Empiric Vancomycin:
- └─► Septic Shock, CLABSI, MRSA Colonization, Skin/Soft Tissue Infection, Severe Mucositis
- Door-to-Antibiotic Emergency Standard
Empiric broad-spectrum IV antibiotics must be administered within 60 minutes of arrival/fever identification ("door-to-antibiotic time < 60 min < 60\text{ min} < 60 min ").
Obtain 2 sets of blood cultures prior to antibiotic infusion (1 peripheral set + 1 set from each lumen of central venous access devices).
First-Line Empiric Regimens
IV Anti-Pseudomonal Monotherapy : Cefepime 2 g IV Q8H, Piperacillin-Tazobactam (Zosyn) 4.5 g IV Q6H, or Meropenem 1 g IV Q8H.
Indications for Adding Empiric Vancomycin : Hemodynamic instability or septic shock; suspected central line-associated bloodstream infection (CLABSI); known MRSA colonization; skin/soft tissue infection; severe grade 3–4 mucositis; radiologic pneumonia.
4. Sepsis & Septic Shock in Oncology
Oncology patients in septic shock exhibit severe dysregulated host response, refractory hypotension, and microvascular hypoperfusion.
Surviving Sepsis Campaign 1-Hour Bundle
Measure serum lactate level; remeasure if initial lactate > 2 mmol/L >2\text{ mmol/L} > 2 mmol/L .
Obtain blood cultures prior to antibiotic administration.
Administer broad-spectrum anti-pseudomonal IV antibiotics.
Rapidly administer 30 mL/kg 30\text{ mL/kg} 30 mL/kg crystalloid bolus for hypotension or lactate ≥ 4 mmol/L \ge 4\text{ mmol/L} ≥ 4 mmol/L .
Apply vasopressors ( Norepinephrine as first-line choice) during or after fluid resuscitation to maintain Mean Arterial Pressure (MAP) ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg .
5. Chemotherapy Vesicant Extravasation Management
Extravasation is the accidental infiltration of a chemotherapy drug into surrounding perivascular tissues. Agents are classified based on tissue toxicity potential:
Vesicant : Causes severe, progressive tissue destruction, blistering, sloughing, tissue necrosis, and loss of function.
Irritant : Causes localized pain, burning, inflammation, or phlebitis along the vein, but without tissue necrosis.
Major Vesicant Drug Classes
Anthracyclines : Doxorubicin, Daunorubicin, Epirubicin, Idarubicin (DNA binding, free radical generation, progressive tissue necrosis).
Vinca Alkaloids : Vincristine, Vinblastine, Vinorelbine (microtubule inhibitors).
Other Vesicants : Mechlorethamine, Dactinomycin, Mitomycin-C, Trabectedin, and Cisplatin at concentrations > 0.5 mg/mL >0.5\text{ mg/mL} > 0.5 mg/mL . The taxanes (paclitaxel, docetaxel) and etoposide are classified by ONS as irritants with vesicant potential — they can blister or cause superficial exfoliation with large-volume extravasation but do not reliably produce full-thickness necrosis.
Universal Extravasation Emergency Protocol
IMMEDIATELY STOP the chemotherapy infusion upon suspicion (pain, burning, swelling, resistance).
Leave the cannula/needle in place. Attach a syringe and aspirate residual drug from the catheter. Do NOT flush the line!
Remove the cannula/needle. Elevate the affected extremity above heart level.
Initiate class-specific thermal application and specific antidote administration.
Class-Specific Thermal & Antidote Matrix
Chemotherapy Class Thermal Application Antidote & Administration Protocol
Anthracyclines ; (Doxorubicin, Epirubicin) Cold Dry Compresses ; (15–20 min QID for 24–48 hrs; causes local vasoconstriction, limiting drug spread). Dexrazoxane (Totect IV) :; Administer IV infusion once daily for 3 consecutive days. Start within 6 hours of extravasation.; • Day 1: 1000 mg/m 2 1000\text{ mg/m}^2 1000 mg/m 2 ; • Day 2: 1000 mg/m 2 1000\text{ mg/m}^2 1000 mg/m 2 ; • Day 3: 500 mg/m 2 500\text{ mg/m}^2 500 mg/m 2 ; (Alternative: Topical 99% Dimethyl Sulfoxide [DMSO] Q6H).
Vinca Alkaloids ; (Vincristine, Vinblastine) Warm Dry Compresses ; (15–20 min QID; causes vasodilation, increasing drug absorption & clearance.; Cold is strictly contraindicated! ) Hyaluronidase (Subcutaneous) :; Inject 150–300 units SC into the extravasation site as 5 to 6 pinwheel injections around the lesion using a 25-gauge needle; a common regimen is 150 units reconstituted to 1 mL and given as five 0.2 mL injections. Degrades extracellular matrix to promote drug dispersion.
Alkylating Agents / Platinums ; (Mechlorethamine, Cisplatin) Cold Dry Compresses ; (Cold compresses reduce tissue reactivity). Sodium Thiosulfate (1/6 Molar) :; Inject SC into extravasation site for mechlorethamine or concentrated cisplatin. Neutralizes reactive alkylating intermediates.